Cannabinoid composition including a cytochrome p450 enzyme inhibitor
The present invention relates to a pharmaceutical composition comprising non-decarboxylated Δ9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resvertrol, and combinations thereof, wherein the composition exhibits an increased but negated psychoactivity with concurrent enhancement in therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.
1. A composition comprising a therapeutically effective amount of Δ9 Tetrahydrocannabinol (THC), Cannabidiol (CBD) and a cytochrome p450 enzyme inhibitor selected from the group consisting of citrus essential oil, citric acid, ascorbic acid, and combinations thereof to enable the composition to have stronger longer-lasting in-vivo effects.
2. A composition comprising a therapeutically effective amount of Cannabidiol (CBD) and a cytochrome p450 enzyme inhibitor to enable the composition to have stronger longer-lasting in-vivo effects, wherein the cytochrome p450 enzyme inhibitor is citrus essential oil.
3. A composition comprising a therapeutically effective amount of Cannabidiol (CBD) and a cytochrome p450 enzyme inhibitor selected from the group consisting of citrus essential oil, citric acid, ascorbic acid, and combinations thereof to enable the composition to have stronger longer-lasting in-vivo effects, wherein the cytochrome p450 enzyme inhibitor is citric acid.
4. A composition comprising a therapeutically effective amount of Cannabidiol (CBD) and a cytochrome p450 enzyme inhibitor selected from the group consisting of citrus essential oil, citric acid, ascorbic acid, and combinations thereof to enable the composition to have stronger longer-lasting in-vivo effects, wherein the cytochrome p450 enzyme inhibitor is ascorbic acid.